Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avian ("Bird") Flu Stocks -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (4)	10/15/2005 11:50:02 PM
From: da_cheif™	Read Replies (1) \| Respond to of 428

so....explain that otherwise that kind of post is worthless.. HEB and its subsidiaries is a biopharmaceutical co. using nucleic acid technologies to develop therapeutic products for the treatment of viral diseases and certain cancers. For the 6 months ended 6/30/05, revenues decreased 13% to $558K. Net loss decreased 51% to $6.9M. Revenues reflect decreased sales of Ampligen(R) under the cost recovery clinical program. Lower loss benefited from the absence of stock compensation charges.